Drawing for ASTEX THERAPEUTICS

USPTO serial 78684737

ASTEX THERAPEUTICS

Reviewed by CopyMark Law Group

Status 605
Filing date
Status date
Registration date
—
Examiner
VALLILLO, MELISSA C
Law office
—

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with ASTEX THERAPEUTICS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Nancy C. DiConza

NANCY C. DICONZA FROSS ZELNICK LEHRMAN & ZISSU PC866 UNITED NATIONS PLZNEW YORK, NY 10017-1822UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001(Based on 44(e)) Chemicals, chemical compounds and chemical preparations for non-medical purposes, namely, those for use in biotechnology; chemicals, chemical compounds and chemical preparations for medical research purposes, namely, those for use in drug discovery and the manufacture or development of pharmaceuticals, not including cardiovascular pharmaceuticals or chemicals for cardiovascular medical purposes; (Based on Intent to Use) diagnostic preparations and/or reagents for clinical or medical laboratory use, not including cardiovascular pharmaceuticals or chemicals for cardiovascular medical purposesABANDONED—
005(Based on Intent to Use) Pharmaceuticals, namely, pharmaceutical preparations for the diagnosis or treatment of diseases and disorders, namely, neurological, dermatological, hematological, bone, respiratory, central nervous system, endrocrinological, circulatory, gastroenterological, hormonal and diabetic disorders, stomach and digestive disorders, muscular and/or rheumatic disorders, immune system disorders, allergic reactions, metabolic disorders, ocular disorders, and for use in oncology; pharmaceuticals, namely, anti-inflammatory agents and anti-infectives; all of the foregoing not including cardiovascular pharmaceuticals or chemicals for cardiovascular medical purposesABANDONED—
009(Based on 44(e)) Computer software for the manipulation and presentation of data for use in relation to drug discovery, biotechnology research and scientific analysisABANDONED—
042(Based on 44(e)) Drug discovery services in the nature of pharmaceutical research and pharmaceutical drug development; biotechnology research; scientific research and analysis in the field of drug discovery and pharmaceutical drug developmentABANDONED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 22, 2011MAB5ABANDONMENT NOTICE MAILED - AFTER PUBLICATION—
Nov 22, 2011ABN5ABANDONMENT - AFTER PUBLICATION—
Nov 15, 2011EXARTEAS EXPRESS ABANDONMENT RECEIVED—
Aug 10, 2011ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Jul 29, 2011CHPBPOST PUBLICATION AMENDMENT - ENTERED—
Jul 25, 2011APETASSIGNED TO PETITION STAFF—
Jul 21, 2011EPPATEAS POST PUBLICATION AMENDMENT RECEIVED—
Jul 12, 2011PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jun 22, 2011NPUBNOTICE OF PUBLICATION—
Jun 6, 2011PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Jun 6, 2011CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
May 26, 2011TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
May 26, 2011CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 12, 2011TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 15, 2010CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 12, 2010CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 22, 2010ACECAMENDMENT FROM APPLICANT ENTERED—
Oct 22, 2010CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 18, 2010MAILPAPER RECEIVED—
Apr 19, 2010CNSIINQUIRY AS TO SUSPENSION MAILED—
Apr 19, 2010CNSISUSPENSION INQUIRY WRITTEN—
Mar 29, 2010RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Sep 28, 2009CNSLLETTER OF SUSPENSION MAILED—
Sep 25, 2009CNSLSUSPENSION LETTER WRITTEN—
Sep 22, 2009ACECAMENDMENT FROM APPLICANT ENTERED—
Sep 22, 2009CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 21, 2009MAILPAPER RECEIVED—
Sep 4, 2009CNSIINQUIRY AS TO SUSPENSION MAILED—
Sep 4, 2009CNSISUSPENSION INQUIRY WRITTEN—
Aug 18, 2009RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Feb 18, 2009CNSLLETTER OF SUSPENSION MAILED—
Feb 18, 2009CNSLSUSPENSION LETTER WRITTEN—
Feb 18, 2009ACECAMENDMENT FROM APPLICANT ENTERED—
Feb 18, 2009CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Feb 17, 2009MAILPAPER RECEIVED—
Feb 5, 2009CNSIINQUIRY AS TO SUSPENSION MAILED—
Feb 5, 2009CNSISUSPENSION INQUIRY WRITTEN—
Jan 17, 2009RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Jul 17, 2008CNSLLETTER OF SUSPENSION MAILED—
Jul 17, 2008CNSLSUSPENSION LETTER WRITTEN—
Jul 16, 2008ACECAMENDMENT FROM APPLICANT ENTERED—
Jul 16, 2008CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 14, 2008MAILPAPER RECEIVED—
Jul 3, 2008CNSIINQUIRY AS TO SUSPENSION MAILED—
Jul 3, 2008CNSISUSPENSION INQUIRY WRITTEN—
Jul 3, 2008RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Jan 3, 2008CNSLLETTER OF SUSPENSION MAILED—
Jan 2, 2008CNSLSUSPENSION LETTER WRITTEN—
Dec 20, 2007ACECAMENDMENT FROM APPLICANT ENTERED—
Dec 20, 2007CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 13, 2007MAILPAPER RECEIVED—
Nov 21, 2007CNSIINQUIRY AS TO SUSPENSION MAILED—
Nov 20, 2007CNSISUSPENSION INQUIRY WRITTEN—
Oct 27, 2007RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Oct 27, 2007ALIEASSIGNED TO LIE—
Apr 26, 2007RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Apr 26, 2007ALIEASSIGNED TO LIE—
Oct 6, 2006CNSLLETTER OF SUSPENSION MAILED—
Oct 6, 2006CNSLSUSPENSION LETTER WRITTEN—
Sep 15, 2006TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Sep 15, 2006CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 15, 2006TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 11, 2006ACECAMENDMENT FROM APPLICANT ENTERED—
Aug 31, 2006CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 31, 2006MAILPAPER RECEIVED—
Feb 28, 2006CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 27, 2006CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 22, 2006DOCKASSIGNED TO EXAMINER—
Aug 9, 2005NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance